Ahmedabad: Zydus Lifesciences Ltd reported a 27% year-on-year decline in consolidated net profit to Rs 925.5 crore for the second quarter of FY27, despite a 29% rise in revenue to Rs 7,909.6 crore.The company’s EBITDA fell 6% to Rs 1,894.5 crore during the quarter. EBITDA margin stood at 24%, compared with the previous year’s level.Zydus invested Rs 657.3 crore in research and development during Q2, equivalent to 8.3% of revenue. Organic capital expenditure stood at Rs 465.5 crore. For the first half of FY27, revenue rose 25% year on year to Rs 15,926.6 crore. Net profit declined 31% to Rs 1,885.9 crore.H1 EBITDA fell 7% to Rs 3,823.9 crore, with margins at 24%. The company invested Rs 1,299.7 crore in R&D, accounting for 8.2% of revenue. Organic capital expenditure during the six months stood at Rs 1,053 crore.As of Sept 30, 2026, Zydus reported a net debt-to-equity ratio of 0.19 times. Its net debt-to-EBITDA ratio stood at 0.62 times. Managing director Sharvil Patel attributed the quarter’s performance to growth across the company’s branded businesses in India, international markets and wellness segments.“The share of branded sales in the US has risen to 16%, underscoring our steady shift towards a more differentiated, speciality-led portfolio. We look forward to the approval and launch of saroglitazar in the US, our first indigenously discovered NCE, which marks a pivotal point in our evolution. Anchored in patient centricity and supported by robust quality systems, we remain committed to building long-term growth levers and enhancing returns for all our stakeholders,” Patel said.
About The Author
